Gene therapy has broken out of its chains. In 2017 alone, Kymriah (Novartis), Luxturna (Spark), and Yescarta (Kite Pharma/Gilead) received FDA approval. The number of small gene therapy companies is […]
News | July 20, 2018
Pacific BioLabs has purchased and validated a QuickPlex SQ 120 MSD instrument and we are now accepting requests for MSD studies. The instrument will be used for immunogenicity testing, biomarker […]
News | June 27, 2018
In the spring of 2018, PBL purchased a SciEx 5600 TripleTOF mass spectrometer. That instrument is now fully validated and ready to use for regulated studies. Please see PBL's blog […]
On July 11th, 2017 the FDA announced that they have determined that certain class II device will no longer meet the premarket notification requirements under section 510(k) of the Federal […]
The path to drug approval involves drug discovery and drug development. In drug discovery, compounds are screened for favorable biological activity against a target(s) and lead compounds are chosen to […]
News | April 17, 2017
Orthopedic Design and Technology Magazine featured Pacific BioLabs in their recent March/April issue. The article discussed new medical device technologies and the testing challenges incurred with these more advanced devices. PBL explains the cleaning, […]